Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mind the Gap: eGFR Discordancy and Melphalan Toxicity in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant.

Kidney360·2026

Same author

Development of Urinalysis Screening Criteria for Rhabdomyolysis in Acute Kidney Injury.

Kidney360·2026

Same author

Glucarpidase for treatment of high-dose methotrexate toxicity.

Blood·2025

Same author

External Validation of an Electronic Health Record-Based Diagnostic Model for Histological Acute Tubulointerstitial Nephritis.

Journal of the American Society of Nephrology : JASN·2024

Same author

A Glimpse into an Editorial Training Program: From the Kidney360 Editorial Program Trainees.

Kidney360·2024

Same author

Exploring the Present and Imagining the Future Landscape of Onconephrology.

Kidney360·2024

Search research articles

Related Experiment Video

Updated: Aug 12, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Chemotherapy-Associated Thrombotic Microangiopathy.

Abinet M Aklilu¹, Anushree C Shirali

¹Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut.

|January 27, 2023

Summary

Drug-induced thrombotic microangiopathy (TMA) complicates cancer treatment, with unclear management strategies. Eculizumab shows promise, but more research is needed to understand this TMA subtype and optimize patient care.

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Aug 12, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

Oncology
Hematology
Nephrology

Background:

Thrombotic microangiopathy (TMA) is a serious condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end-organ damage.
While primary TMAs have improved management, secondary TMAs, especially those induced by drugs, present significant clinical challenges.
Cancer therapies, including chemotherapy and targeted agents, are increasingly implicated in causing TMA, disrupting cancer treatment and worsening prognosis.

Purpose of the Study:

To review the current understanding of drug-induced TMA in the context of cancer therapy.
To discuss the diagnostic and management challenges associated with chemotherapy-associated TMA.
To explore potential therapeutic strategies, including the role of complement inhibition.

Main Methods:

Literature review of studies on drug-induced TMA in cancer patients.
Analysis of treatment outcomes for various interventions, including drug withdrawal, supportive care, and targeted therapies.
Evaluation of existing data on the efficacy of eculizumab in chemotherapy-associated TMA.

Main Results:

Drug-induced TMA complicates oncotherapy, necessitating treatment modifications and potentially leading to cancer progression.
Standard treatments like immunosuppression and plasma exchange lack clear benefit for drug-induced TMA.
Eculizumab has demonstrated potential efficacy in select cases of chemotherapy-associated TMA, though data remain limited.

Conclusions:

Drug-induced TMA is a poorly understood complication of cancer treatment with significant implications for patient outcomes.
Withdrawal of the offending agent and supportive care are primary management strategies.
Further research, including large multicenter studies and standardized definitions, is crucial to clarify the role of complement and establish optimal treatment protocols for drug-induced TMA.